SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.  Helen Torley, president and chief executive officer of Halozyme, shared the following statement:"We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies wi ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...

Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologiesWould meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyondAll-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("H ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry TeamSAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. T ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio.It has been over two years since my previous Halozyme (NASDAQ: HALO ) article , where I discussed Halozyme's acquisition of Antares Pharma for roughly $960M, which was expected to improve their growth trajectory thanks to the addition of Antares Pharma' ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Halozyme Therapeutics, Inc. (HALO) reported third-quarter 2024 adjusted earnings of $1.27 per share, which comprehensively beat the Zacks Consensus Estimate of 99 cents. The company had recorded adjusted earnings of 75 cents per share in the year-ago period.Total revenues in the third quarter increased 34% year over year to $290 million. Revenues surpassed the Zacks Consensus Estimate of $248 million.The top line was primarily driven by higher royalty payments from Roche (RHHBY) for Phesgo and J&J (JNJ) for ...

Financial Data and Key Metrics Changes - Total revenues increased by 34% to reach an all-time high of $290 million in Q3 2024, driven largely by a 36% increase in royalty revenue to $155 million [7][63] - Adjusted EBITDA grew by 60% to $183.6 million, while non-GAAP earnings per share increased by 69% to $1.27 [62][66] - The company raised its full-year revenue guidance to $970 million to $1.20 billion, representing a year-over-year increase of 17% to 23% [68][70] Business Line Data and Key Metrics Changes - Royalty revenues from subcutaneous DARZALEX, Phesgo, and VYVGART Hytrulo were the main drivers of growth, with DARZALEX sales increasing almost 23% and Phesgo sales up 58% [22][26][64] - Collaboration revenues rose significantly to $48.4 million, compared to $15 million in the prior year, due to the expansion of the Argenx collaboration [64] Market Data and Key Metrics Changes - The U.S. approval of Roche's TECENTRIQ and OCREVUS subcutaneous formulations is expected to expand market opportunities significantly, with Roche projecting a $2 billion market expansion for OCREVUS [10][31][76] - Analysts predict TECENTRIQ will achieve $5 billion in sales by 2028, with a significant portion coming from the conversion of intravenous to subcutaneous administration [30] Company Strategy and Development Direction - The company is focused on expanding its ENHANZE drug delivery technology through new partnerships and licensing agreements, with recent expansions including argenx's nomination of four additional targets [9][17] - The strategy emphasizes market growth rather than immediate conversion from IV to subcutaneous, particularly for OCREVUS, which aims to attract new prescribers [75][81] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued double-digit growth driven by multiple product launches and regulatory approvals, setting the stage for a strong start to 2025 [72][54] - The company highlighted the importance of its intellectual property portfolio in supporting revenue streams and enabling new partnerships [55][60] Other Important Information - The company maintains a strong balance sheet with cash and marketable securities totaling $666.3 million as of September 30, 2024 [67] - The MDASE patent portfolio has been expanded, with nearly 100 patents granted or pending, providing additional opportunities for licensing [59][116] Q&A Session Summary Question: Current view on sub-Q conversion for OCREVUS and TECENTRIQ - Management clarified that OCREVUS aims for market growth rather than immediate conversion, projecting a $2 billion market expansion, while TECENTRIQ will focus on converting existing patients to subcutaneous [75][76][81] Question: Contextualizing the $2 billion market expansion for OCREVUS - Management indicated that the $2 billion is additional to the existing IV sales, suggesting a total market growth to approximately $11 billion [81] Question: Status of new collaboration deals before year-end - Management confirmed ongoing efforts to secure new deals, with guidance for collaboration revenue set at $130 million to $150 million [87][88] Question: Differentiation of MDASE from ENHANZE - Management explained that MDASE involves different structures and is not expected to infringe on existing ENHANZE partnerships, as they cater to different needs [111][114] Question: Examples of partners unable to work with ENHANZE - Management noted that partners might choose modified hyaluronidase if they cannot work with ENHANZE due to exclusive licensing agreements [120] Question: Drivers behind the collaboration revenue guidance - Management acknowledged a slight reduction in the top range of collaboration revenue guidance, attributing it to current visibility on potential deals [119]